Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891926228> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2891926228 endingPage "2509" @default.
- W2891926228 startingPage "2509" @default.
- W2891926228 abstract "2509 Background: MTL-CEBPA is a liposomal formulation of saRNA targeting the transcription factor C/EBP-α, which acts as a master regulator of liver homeostasis and multiple oncogenic processes including cell cycle control, proliferation and angiogenesis and inhibits hepatocellular cancer (HCC) tumor growth in preclinical models. MTL-CEBPA is the first saRNA and the first drug targeting C/EBP-α entering clinical trials. Methods: Patients (pts) with advanced HCC (Child-Pugh A/B) or secondary liver cancer, were enrolled in a 3+3 dose escalation study. MTL-CEBPA is administered as a 1-hr IV infusion on Day 1, 8 and 15 of a 28 day cycle. The primary endpoint was safety and the secondary endpoints included PK, liver function improvement and anti-tumor activity. Correlative studies include C/EBP-α mRNA levels in PBMCs and tumor tissue, evaluation of C/EBP-α downstream target genes (e.g.TGFβ) and distal target engagement in WBCs (e.g.IL-6, NF-κB). Results: 19 participants have been treated across 5 dose levels (28-130 mg/m2): 13M/6F, median age 67 yrs (range 27 - 80), ECOG PS 0/1: 9/10. Tumour types include HCC (13), colorectal (4) and fibrolamellar (2). The most common treatment-related AEs (all grades/grade 3) include fatigue (9/1), diarrhoea (5/0), AST increase (5/1), low platelets (2/1) hyperbilirubinaemia (5/1) and hypophosphataemia (4/1). Maximum tolerated dose has not yet been reached. Serum PK analysis shows a terminal half life of > 24 hrs, with dose proportional Cmax and AUC. Analysis of WBCs showed a significant increase of C/EBP-α expression during treatment providing evidence of target engagement. Of 10 evaluable pts with HCC, 4 pts have had SD≥ 4months, with one patient having an ongoing PR for 18 months associated with 73% decrease in tumour volume and reduction in IL-6, NF-κB and IFN-γ. Conclusions: Once weekly MTL-CEBPA therapy was well tolerated, shows promising PD and initial clinical response in patients with advanced HCC. Updated results for the dose escalation will be presented. Clinical trial information: NCT02716012." @default.
- W2891926228 created "2018-09-27" @default.
- W2891926228 creator A5017721654 @default.
- W2891926228 creator A5025272654 @default.
- W2891926228 creator A5033962986 @default.
- W2891926228 creator A5038656790 @default.
- W2891926228 creator A5043533251 @default.
- W2891926228 creator A5045076272 @default.
- W2891926228 creator A5053323102 @default.
- W2891926228 creator A5060350068 @default.
- W2891926228 creator A5078706966 @default.
- W2891926228 creator A5080885887 @default.
- W2891926228 creator A5089670001 @default.
- W2891926228 date "2018-05-20" @default.
- W2891926228 modified "2023-10-14" @default.
- W2891926228 title "Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C/EBP-α in patients with advanced liver cancer." @default.
- W2891926228 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.2509" @default.
- W2891926228 hasPublicationYear "2018" @default.
- W2891926228 type Work @default.
- W2891926228 sameAs 2891926228 @default.
- W2891926228 citedByCount "6" @default.
- W2891926228 countsByYear W28919262282018 @default.
- W2891926228 countsByYear W28919262282021 @default.
- W2891926228 crossrefType "journal-article" @default.
- W2891926228 hasAuthorship W2891926228A5017721654 @default.
- W2891926228 hasAuthorship W2891926228A5025272654 @default.
- W2891926228 hasAuthorship W2891926228A5033962986 @default.
- W2891926228 hasAuthorship W2891926228A5038656790 @default.
- W2891926228 hasAuthorship W2891926228A5043533251 @default.
- W2891926228 hasAuthorship W2891926228A5045076272 @default.
- W2891926228 hasAuthorship W2891926228A5053323102 @default.
- W2891926228 hasAuthorship W2891926228A5060350068 @default.
- W2891926228 hasAuthorship W2891926228A5078706966 @default.
- W2891926228 hasAuthorship W2891926228A5080885887 @default.
- W2891926228 hasAuthorship W2891926228A5089670001 @default.
- W2891926228 hasConcept C104317684 @default.
- W2891926228 hasConcept C126322002 @default.
- W2891926228 hasConcept C143998085 @default.
- W2891926228 hasConcept C2776231280 @default.
- W2891926228 hasConcept C2778019345 @default.
- W2891926228 hasConcept C45091340 @default.
- W2891926228 hasConcept C502942594 @default.
- W2891926228 hasConcept C55493867 @default.
- W2891926228 hasConcept C71924100 @default.
- W2891926228 hasConcept C86339819 @default.
- W2891926228 hasConcept C86803240 @default.
- W2891926228 hasConcept C98274493 @default.
- W2891926228 hasConceptScore W2891926228C104317684 @default.
- W2891926228 hasConceptScore W2891926228C126322002 @default.
- W2891926228 hasConceptScore W2891926228C143998085 @default.
- W2891926228 hasConceptScore W2891926228C2776231280 @default.
- W2891926228 hasConceptScore W2891926228C2778019345 @default.
- W2891926228 hasConceptScore W2891926228C45091340 @default.
- W2891926228 hasConceptScore W2891926228C502942594 @default.
- W2891926228 hasConceptScore W2891926228C55493867 @default.
- W2891926228 hasConceptScore W2891926228C71924100 @default.
- W2891926228 hasConceptScore W2891926228C86339819 @default.
- W2891926228 hasConceptScore W2891926228C86803240 @default.
- W2891926228 hasConceptScore W2891926228C98274493 @default.
- W2891926228 hasIssue "15_suppl" @default.
- W2891926228 hasLocation W28919262281 @default.
- W2891926228 hasOpenAccess W2891926228 @default.
- W2891926228 hasPrimaryLocation W28919262281 @default.
- W2891926228 hasRelatedWork W2020483997 @default.
- W2891926228 hasRelatedWork W2021080195 @default.
- W2891926228 hasRelatedWork W2328603980 @default.
- W2891926228 hasRelatedWork W2587321528 @default.
- W2891926228 hasRelatedWork W3022463795 @default.
- W2891926228 hasRelatedWork W3091218766 @default.
- W2891926228 hasRelatedWork W3091350106 @default.
- W2891926228 hasRelatedWork W3178156607 @default.
- W2891926228 hasRelatedWork W4239256621 @default.
- W2891926228 hasRelatedWork W4383315843 @default.
- W2891926228 hasVolume "36" @default.
- W2891926228 isParatext "false" @default.
- W2891926228 isRetracted "false" @default.
- W2891926228 magId "2891926228" @default.
- W2891926228 workType "article" @default.